{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31894299", "DateCompleted": {"Year": "2020", "Month": "10", "Day": "15"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "12", "Day": "16"}], "Language": ["eng"], "ELocationID": ["10.3892/ijo.2019.4943"], "Journal": {"ISSN": "1791-2423", "JournalIssue": {"Volume": "56", "Issue": "2", "PubDate": {"Year": "2020", "Month": "Feb"}}, "Title": "International journal of oncology", "ISOAbbreviation": "Int J Oncol"}, "ArticleTitle": "FLI1 promotes protein translation via the transcriptional regulation of MKNK1 expression.", "Pagination": {"StartPage": "430", "EndPage": "438", "MedlinePgn": "430-438"}, "Abstract": {"AbstractText": ["The disruption of protein translation machinery is a common feature of cancer initiation and progression, and drugs that target protein translation offer new avenues for therapy. The translation initiation factor, eukaryotic initiation factor 4E (eIF4E), is induced in a number of cancer cell lines and is one such candidate for therapeutic intervention. Friend leukemia integration 1 (FLI1) is a potent oncogenic transcription factor that promotes various types of cancer by promoting several hallmarks of cancer progression. FLI1 has recently been implicated in protein translation through yet unknown mechanisms. This study identified a positive association between FLI1 expression and mitogen\u2011activated protein kinase (MAPK)\u2011interacting serine/threonine kinase1 (MKNK1), the immediate upstream regulator of the eIF4E initiation factor. The short hairpin RNA (shRNA)\u2011mediated silencing or overexpression of FLI1 in leukemic cell lines downregulated or upregulated MKNK1 expression, respectively. Promoter analysis identified a potent FLI1 binding site in the regulatory region of the MKNK1 promoter. In transient transfection experiments, FLI1 increased MKNK1 promoter activity, which was blocked by mutating the FLI1 binding site. FLI1 specifically affected the expression of MKNK1, but not that of MKNK2. The siRNA\u2011mediated downregulation of MKNK1 downregulated the expression of survivin (BIRC5) and significantly suppressed cell proliferation in culture. FLI1 inhibitory compounds were shown to downregulate this oncogene through the suppression of MAPK/extracellular\u2011regulated kinase (ERK) signaling and the subsequent activation of miR\u2011145, leading to a lower MKNK1 expression and the suppression of leukemic growth. These results uncover a critical role for FLI1 in the control of protein translation and the importance of targeting its function and downstream mediators, such as MKNK1, for cancer therapy."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Province Science City, High Tech Zone, Baiyun, Guiyang, Guizhou 550014, P.R. China."}], "LastName": "Wang", "ForeName": "Chunlin", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Province Science City, High Tech Zone, Baiyun, Guiyang, Guizhou 550014, P.R. China."}], "LastName": "Song", "ForeName": "Jialei", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Province Science City, High Tech Zone, Baiyun, Guiyang, Guizhou 550014, P.R. China."}], "LastName": "Liu", "ForeName": "Wuling", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Province Science City, High Tech Zone, Baiyun, Guiyang, Guizhou 550014, P.R. China."}], "LastName": "Yao", "ForeName": "Yao", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Genomics, School of Biomedical Sciences, Huaqiao University, Xiamen, Fujian 361021, P.R. China."}], "LastName": "Kapranov", "ForeName": "Philipp", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Guizhou Provincial People's Hospital, The Affiliated Hospital of Guizhou University Medical College, Guiyang, Guizhou 550002, P.R. China."}], "LastName": "Sample", "ForeName": "Klarke M", "Initials": "KM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Province Science City, High Tech Zone, Baiyun, Guiyang, Guizhou 550014, P.R. China."}], "LastName": "Gajendran", "ForeName": "Babu", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada."}], "LastName": "Zacksenhaus", "ForeName": "Eldad", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Province Science City, High Tech Zone, Baiyun, Guiyang, Guizhou 550014, P.R. China."}], "LastName": "Hao", "ForeName": "Xiaojiang", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Province Science City, High Tech Zone, Baiyun, Guiyang, Guizhou 550014, P.R. China."}], "LastName": "Ben-David", "ForeName": "Yaacov", "Initials": "Y"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Greece", "MedlineTA": "Int J Oncol", "NlmUniqueID": "9306042", "ISSNLinking": "1019-6439"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Aniline Compounds"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "BIRC5 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "CGP 57380"}, {"RegistryNumber": "0", "NameOfSubstance": "EIF4E protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Eukaryotic Initiation Factor-4E"}, {"RegistryNumber": "0", "NameOfSubstance": "FLI1 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Intracellular Signaling Peptides and Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "MIRN145 microRNA, human"}, {"RegistryNumber": "0", "NameOfSubstance": "MicroRNAs"}, {"RegistryNumber": "0", "NameOfSubstance": "Proto-Oncogene Protein c-fli-1"}, {"RegistryNumber": "0", "NameOfSubstance": "Purines"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Small Interfering"}, {"RegistryNumber": "0", "NameOfSubstance": "Survivin"}, {"RegistryNumber": "EC 2.7.1.-", "NameOfSubstance": "MKNK1 protein, human"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "MKNK2 protein, human"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Protein Serine-Threonine Kinases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Aniline Compounds"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["metabolism"], "DescriptorName": "Eukaryotic Initiation Factor-4E"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression Regulation, Neoplastic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["antagonists & inhibitors", "genetics", "metabolism"], "DescriptorName": "Intracellular Signaling Peptides and Proteins"}, {"QualifierName": ["drug therapy", "genetics", "pathology"], "DescriptorName": "Leukemia, Erythroblastic, Acute"}, {"QualifierName": ["drug effects"], "DescriptorName": "MAP Kinase Signaling System"}, {"QualifierName": ["metabolism"], "DescriptorName": "MicroRNAs"}, {"QualifierName": ["drug effects", "genetics"], "DescriptorName": "Phosphorylation"}, {"QualifierName": ["genetics"], "DescriptorName": "Promoter Regions, Genetic"}, {"QualifierName": ["drug effects", "genetics"], "DescriptorName": "Protein Biosynthesis"}, {"QualifierName": ["antagonists & inhibitors", "genetics", "metabolism"], "DescriptorName": "Protein Serine-Threonine Kinases"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Proto-Oncogene Protein c-fli-1"}, {"QualifierName": [], "DescriptorName": "Purines"}, {"QualifierName": ["metabolism"], "DescriptorName": "RNA, Small Interfering"}, {"QualifierName": ["metabolism"], "DescriptorName": "Survivin"}, {"QualifierName": ["drug effects", "genetics"], "DescriptorName": "Transcription, Genetic"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015;14:261\u2013278. doi: 10.1038/nrd4505.", "ArticleIdList": ["10.1038/nrd4505", "25743081"]}, {"Citation": "Chu J, Pelletier J. Therapeutic opportunities in eukaryotic translation. Cold Spring Harb Perspect Biol. 2018;10:a032995. doi: 10.1101/cshperspect.a032995.", "ArticleIdList": ["10.1101/cshperspect.a032995", "PMC5983196", "29440069"]}, {"Citation": "Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol. 1999;19:1871\u20131880. doi: 10.1128/MCB.19.3.1871.", "ArticleIdList": ["10.1128/MCB.19.3.1871", "PMC83980", "10022874"]}, {"Citation": "Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997;16:1909\u20131920. doi: 10.1093/emboj/16.8.1909.", "ArticleIdList": ["10.1093/emboj/16.8.1909", "PMC1169794", "9155017"]}, {"Citation": "Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 1999;18:270\u2013279. doi: 10.1093/emboj/18.1.270.", "ArticleIdList": ["10.1093/emboj/18.1.270", "PMC1171121", "9878069"]}, {"Citation": "Siddiqui N, Sonenberg N. Signalling to eIF4E in cancer. Biochem Soc Trans. 2015;43:763\u2013772. doi: 10.1042/BST20150126.", "ArticleIdList": ["10.1042/BST20150126", "PMC4613458", "26517881"]}, {"Citation": "Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, Mohr E, Massimi M, Falconi M, et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell. 2008;134:1042\u20131054. doi: 10.1016/j.cell.2008.07.031.", "ArticleIdList": ["10.1016/j.cell.2008.07.031", "18805096"]}, {"Citation": "Jauch R, J\u00e4kel S, Netter C, Schreiter K, Aicher B, J\u00e4ckle H, Wahl MC. Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site. Structure. 2005;13:1559\u20131568. doi: 10.1016/j.str.2005.07.013.", "ArticleIdList": ["10.1016/j.str.2005.07.013", "16216586"]}, {"Citation": "Jauch R, Cho MK, J\u00e4kel S, Netter C, Schreiter K, Aicher B, Zweckstetter M, J\u00e4ckle H, Wahl MC. Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment. EMBO J. 2006;25:4020\u20134032. doi: 10.1038/sj.emboj.7601285.", "ArticleIdList": ["10.1038/sj.emboj.7601285", "PMC1560367", "16917500"]}, {"Citation": "Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24:6539\u20136549. doi: 10.1128/MCB.24.15.6539-6549.2004.", "ArticleIdList": ["10.1128/MCB.24.15.6539-6549.2004", "PMC444855", "15254222"]}, {"Citation": "Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R, Wang S. MAP kinase-interacting kinases-emerging targets against cancer. Chem Biol. 2014;21:441\u2013452. doi: 10.1016/j.chembiol.2014.01.011.", "ArticleIdList": ["10.1016/j.chembiol.2014.01.011", "24613018"]}, {"Citation": "Ben-David Y, Bernstein A. Friend virus-induced erythro-leukemia and the multistage nature of cancer. Cell. 1991;66:831\u2013834. doi: 10.1016/0092-8674(91)90428-2.", "ArticleIdList": ["10.1016/0092-8674(91)90428-2", "1889087"]}, {"Citation": "Ben-David Y, Giddens EB, Bernstein A. Identification and mapping of a common proviral integration site Fli-1 in erythro-leukemia cells induced by Friend murine leukemia virus. Proc Natl Acad Sci USA. 1990;87:1332\u20131336. doi: 10.1073/pnas.87.4.1332.", "ArticleIdList": ["10.1073/pnas.87.4.1332", "PMC53469", "2304901"]}, {"Citation": "Ben-David Y, Giddens EB, Letwin K, Bernstein A. Erythroleukemia induction by Friend murine leukemia virus: Insertional activation of a new member of the ets gene family, Fli-1, closely linked to c-ets-1. Genes Dev. 1991;5:908\u2013918. doi: 10.1101/gad.5.6.908.", "ArticleIdList": ["10.1101/gad.5.6.908", "2044959"]}, {"Citation": "Li Y, Luo H, Liu T, Zacksenhaus E, Ben-David Y. The ets transcription factor Fli-1 in development, cancer and disease. Oncogene. 2015;34:2022\u20132031. doi: 10.1038/onc.2014.162.", "ArticleIdList": ["10.1038/onc.2014.162", "PMC5028196", "24909161"]}, {"Citation": "Lou N, Lennard Richard ML, Yu J, Kindy M, Zhang XK. The Fli-1 transcription factor is a critical regulator for controlling the expression of chemokine C-X-C motif ligand 2 (CXCL2) Mol Immunol. 2017;81:59\u201366. doi: 10.1016/j.molimm.2016.11.007.", "ArticleIdList": ["10.1016/j.molimm.2016.11.007", "27889620"]}, {"Citation": "Sato S, Zhang XK. The Friend leukaemia virus integration 1 (Fli-1) transcription factor affects lupus nephritis development by regulating inflammatory cell infiltration into the kidney. Clin Exp Immunol. 2014;177:102\u2013109. doi: 10.1111/cei.12310.", "ArticleIdList": ["10.1111/cei.12310", "PMC4089159", "24580413"]}, {"Citation": "Liu T, Yao Y, Zhang G, Wang Y, Deng B, Song J, Li X, Han F, Xiao X, Yang J, et al. A screen for Fli-1 transcriptional modulators identifies PKC agonists that induce erythroid to megakaryocytic differentiation and suppress leukemogenesis. Oncotarget. 2017;8:16728\u201316743.", "ArticleIdList": ["PMC5369997", "28052010"]}, {"Citation": "Cui JW, Vecchiarelli-Federico LM, Li YJ, Wang GJ, Ben-David Y. Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia. Leukemia. 2009;23:1311\u20131319. doi: 10.1038/leu.2009.20.", "ArticleIdList": ["10.1038/leu.2009.20", "19282832"]}, {"Citation": "Li YJ, Zhao X, Vecchiarelli-Federico LM, Li Y, Datti A, Cheng Y, Ben-David Y. Drug-mediated inhibition of Fli-1 for the treatment of leukemia. Blood Cancer J. 2012;2:e54. doi: 10.1038/bcj.2011.52.", "ArticleIdList": ["10.1038/bcj.2011.52", "PMC3270256", "22829238"]}, {"Citation": "Liu T, Xia L, Yao Y, Yan C, Fan Y, Gajendran B, Yang J, Li YJ, Chen J, Filmus J, et al. Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogen-esis. Cell Death Dis. 2019;10:117. doi: 10.1038/s41419-019-1363-1.", "ArticleIdList": ["10.1038/s41419-019-1363-1", "PMC6370842", "30741932"]}, {"Citation": "Song J, Yuan C, Yang J, Liu T, Yao Y, Xiao X, Gajendran B, Xu D, Li YJ, Wang C, et al. Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia. FEBS J. 2018;285:4631\u20134645. doi: 10.1111/febs.14690.", "ArticleIdList": ["10.1111/febs.14690", "30387554"]}, {"Citation": "Vecchiarelli-Federico LM, Liu T, Yao Y, Gao Y, Li Y, Li YJ, Ben-David Y. Fli-1 overexpression in erythroleukemic cells promotes erythroid de-differentiation while Spi-1/PU.1 exerts the opposite effect. Int J Oncol. 2017;51:456\u2013466. doi: 10.3892/ijo.2017.4027.", "ArticleIdList": ["10.3892/ijo.2017.4027", "PMC5505126", "28586009"]}, {"Citation": "De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23:3189\u20133199. doi: 10.1038/sj.onc.1207545.", "ArticleIdList": ["10.1038/sj.onc.1207545", "15094768"]}, {"Citation": "Cong XL, Han ZC. Survivin and leukemia. Int J Hematol. 2004;80:232\u2013238. doi: 10.1532/IJH97.A10408.", "ArticleIdList": ["10.1532/IJH97.A10408", "15540897"]}, {"Citation": "Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, Schaefer KL, Nakatani F, Scotlandi K, Reiter M, et al. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing\u2019s sarcoma. Oncogene. 2011;30:2173\u20132180. doi: 10.1038/onc.2010.581.", "ArticleIdList": ["10.1038/onc.2010.581", "PMC4959567", "21217773"]}, {"Citation": "Wu P, Liang J, Yu F, Zhou Z, Tang J, Li K. miR-145 promotes osteosarcoma growth by reducing expression of the transcription factor friend leukemia virus integration 1. Oncotarget. 2016;7:42241\u201342251.", "ArticleIdList": ["PMC5173131", "27304058"]}, {"Citation": "Zhang J, Guo H, Zhang H, Wang H, Qian G, Fan X, Hoffman AR, Hu JF, Ge S. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011;117:86\u201395. doi: 10.1002/cncr.25522.", "ArticleIdList": ["10.1002/cncr.25522", "PMC2995010", "20737575"]}, {"Citation": "Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genov\u00e9 G, Arrondel C, Gerwins P, Kurschat C, Schermer B, et al. Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1. Genome Med. 2009;1:108. doi: 10.1186/gm108.", "ArticleIdList": ["10.1186/gm108", "PMC2808743", "19917099"]}, {"Citation": "Wang S, Liu JC, Ju Y, Pellecchia G, Voisin V, Wang DY, Leha LR, Ben-David Y, Bader GD, Zacksenhaus E. microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. JCI Insight. 2017;2:93313. doi: 10.1172/jci.insight.93313.", "ArticleIdList": ["10.1172/jci.insight.93313", "PMC5543917", "28768903"]}, {"Citation": "Wheatley SP, Altieri DC. Survivin at a glance. J Cell Sci. 2019;132:jcs223826. doi: 10.1242/jcs.223826.", "ArticleIdList": ["10.1242/jcs.223826", "PMC6467487", "30948431"]}, {"Citation": "Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: A unique target for tumor therapy. Cancer Cell Int. 2016;16:49. doi: 10.1186/s12935-016-0326-1.", "ArticleIdList": ["10.1186/s12935-016-0326-1", "PMC4917988", "27340370"]}]}], "History": [{"Year": "2019", "Month": "7", "Day": "25"}, {"Year": "2019", "Month": "11", "Day": "18"}, {"Year": "2020", "Month": "1", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "10", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "12", "Day": "16"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31894299", "PMC6959374", "10.3892/ijo.2019.4943"]}}]}